NEW YORK (TheStreet) -- Pfizer(PFE) - Get Report shares are down by 0.53% to $34.08 in late morning trading on Monday, one day ahead of the release of the global pharmaceutical company's second quarter financial results.
Pfizer will report its earnings results before the market open tomorrow.
The company is expected to post earnings of 52 cents per share on revenue of $11.4 billion for the period.
Those results would be a decline from the year ago quarter, when Pfizer earned 58 cents per share on revenue of $12.7 billion.
Pfizer has beaten consensus earnings estimates in 10 of the last 11 quarters, with one quarter of earnings that were in line with analysts expectations.
Earlier this year, Pfizer acquired Hospira (HSP) for $17 billion and said that it is not done acquiring companies.
Separately, TheStreet Ratings team rates PFIZER INC as a Buy with a ratings score of A-. TheStreet Ratings Team has this to say about their recommendation:
"We rate PFIZER INC (PFE) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its solid stock price performance, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, expanding profit margins and growth in earnings per share. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity."